1. Effect of Anti-Glutamate Antibodies in Modeled Parkinsonian Syndrome.
- Author
-
Kucheryanu VG, Vetrile LA, Zakharova IA, and Voronina NA
- Subjects
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration & dosage, Administration, Intranasal, Animals, Antibodies chemistry, Antibodies isolation & purification, Antiparkinson Agents chemistry, Antiparkinson Agents isolation & purification, Autoantibodies biosynthesis, Dopamine chemistry, Glutamic Acid chemistry, Horses, Hypokinesia chemically induced, Hypokinesia immunology, Hypokinesia physiopathology, Immunoconjugates administration & dosage, Immunoconjugates chemistry, Male, Mice, Mice, Inbred C57BL, Parkinsonian Disorders chemically induced, Parkinsonian Disorders immunology, Parkinsonian Disorders physiopathology, Rabbits, gamma-Globulins chemistry, gamma-Globulins immunology, Antibodies pharmacology, Antiparkinson Agents pharmacology, Dopamine immunology, Glutamic Acid immunology, Hypokinesia drug therapy, Parkinsonian Disorders drug therapy
- Abstract
We studied the effect of single and repeated intranasal administration of antibodies to glutamate in experimental parkinsonian syndrome induced by injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to C57BL/6J mice. Intranasal administration of anti-glutamate antibodies to mice in parallel with administration of MPTP over 10 days alleviated parkinsonian symptoms (oligokinesia and rigidity). In the serum of mice injected with antibodies to glutamate and/or MPTP, the titers of autoantibodies to glutamate and dopamine were higher than in control animals receiving saline. Single intranasal administration of anti-glutamate antibodies to mice with established parkinsonian syndrome did not affect the severity of parkinsonian symptoms.
- Published
- 2020
- Full Text
- View/download PDF